BPC
BCRX icon

Banque Pictet & Cie’s BioCryst Pharmaceuticals BCRX Stock Holding History

Banque Pictet & Cie’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-87,400
Closed -$925 – 615
2022
Q2 		$925 Buy
+87,400
New +$902K 0.01% 443

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Banque Pictet & Cie's BCRX Position: Q3 2022 in Review

Banque Pictet & Cie sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2022, closing a stake of 87,400 shares — an estimated $925 sold.

Banque Pictet & Cie first reported a position in BCRX in Q2 2022 and held it in 1 quarter. The position peaked at $925 in Q2 2022. 234 funds tracked by Wall St. Rank hold BCRX as of Q3 2022.

  • Banque Pictet & Cie reported no remaining BioCryst Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Banque Pictet & Cie sold 87,400 BioCryst Pharmaceuticals shares in Q3 2022, an estimated $925.
  • Banque Pictet & Cie first reported a position in BioCryst Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Banque Pictet & Cie's BioCryst Pharmaceuticals position peaked at $925 in Q2 2022.
  • 234 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2022.

Based on Banque Pictet & Cie's 13F filing for Q3 2022, filed 10 Nov 2022.